Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

NCT05201404 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT05201404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05201404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Lead sponsor
Can-Fite BioPharma
Phase
Phase 3
Overall status
Recruiting
Start date
March 15, 2023
Completion date
October 31, 2026
Enrollment
471 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatocellular carcinoma